S&P 500   3,344.41 (-0.14%)
DOW   27,305.70 (-0.30%)
QQQ   273.81 (-0.30%)
AAPL   452.59 (-0.66%)
MSFT   214.95 (-0.65%)
FB   275.70 (+3.93%)
GOOGL   1,512.50 (+0.50%)
AMZN   3,220.89 (-0.13%)
NVDA   455.92 (+0.55%)
CGC   17.13 (-2.23%)
BABA   255.90 (-3.68%)
TSLA   1,482.01 (-0.51%)
MU   48.73 (+0.06%)
GE   6.31 (-0.32%)
AMD   86.12 (-0.68%)
T   29.65 (-0.64%)
F   6.84 (-1.30%)
ACB   10.24 (-0.68%)
GILD   68.98 (+0.25%)
NFLX   501.74 (-1.44%)
DIS   131.65 (+0.63%)
BAC   25.43 (-0.16%)
BA   171.63 (-0.33%)
S&P 500   3,344.41 (-0.14%)
DOW   27,305.70 (-0.30%)
QQQ   273.81 (-0.30%)
AAPL   452.59 (-0.66%)
MSFT   214.95 (-0.65%)
FB   275.70 (+3.93%)
GOOGL   1,512.50 (+0.50%)
AMZN   3,220.89 (-0.13%)
NVDA   455.92 (+0.55%)
CGC   17.13 (-2.23%)
BABA   255.90 (-3.68%)
TSLA   1,482.01 (-0.51%)
MU   48.73 (+0.06%)
GE   6.31 (-0.32%)
AMD   86.12 (-0.68%)
T   29.65 (-0.64%)
F   6.84 (-1.30%)
ACB   10.24 (-0.68%)
GILD   68.98 (+0.25%)
NFLX   501.74 (-1.44%)
DIS   131.65 (+0.63%)
BAC   25.43 (-0.16%)
BA   171.63 (-0.33%)
S&P 500   3,344.41 (-0.14%)
DOW   27,305.70 (-0.30%)
QQQ   273.81 (-0.30%)
AAPL   452.59 (-0.66%)
MSFT   214.95 (-0.65%)
FB   275.70 (+3.93%)
GOOGL   1,512.50 (+0.50%)
AMZN   3,220.89 (-0.13%)
NVDA   455.92 (+0.55%)
CGC   17.13 (-2.23%)
BABA   255.90 (-3.68%)
TSLA   1,482.01 (-0.51%)
MU   48.73 (+0.06%)
GE   6.31 (-0.32%)
AMD   86.12 (-0.68%)
T   29.65 (-0.64%)
F   6.84 (-1.30%)
ACB   10.24 (-0.68%)
GILD   68.98 (+0.25%)
NFLX   501.74 (-1.44%)
DIS   131.65 (+0.63%)
BAC   25.43 (-0.16%)
BA   171.63 (-0.33%)
S&P 500   3,344.41 (-0.14%)
DOW   27,305.70 (-0.30%)
QQQ   273.81 (-0.30%)
AAPL   452.59 (-0.66%)
MSFT   214.95 (-0.65%)
FB   275.70 (+3.93%)
GOOGL   1,512.50 (+0.50%)
AMZN   3,220.89 (-0.13%)
NVDA   455.92 (+0.55%)
CGC   17.13 (-2.23%)
BABA   255.90 (-3.68%)
TSLA   1,482.01 (-0.51%)
MU   48.73 (+0.06%)
GE   6.31 (-0.32%)
AMD   86.12 (-0.68%)
T   29.65 (-0.64%)
F   6.84 (-1.30%)
ACB   10.24 (-0.68%)
GILD   68.98 (+0.25%)
NFLX   501.74 (-1.44%)
DIS   131.65 (+0.63%)
BAC   25.43 (-0.16%)
BA   171.63 (-0.33%)
Log in

NYSE:DGXQuest Diagnostics Stock Price, Forecast & News

$125.16
+0.65 (+0.52 %)
(As of 08/7/2020 11:28 AM ET)
Add
Compare
Today's Range
$124.78
Now: $125.16
$126.07
50-Day Range
$104.55
MA: $119.01
$130.01
52-Week Range
$73.02
Now: $125.16
$131.81
Volume7,655 shs
Average Volume1.43 million shs
Market Capitalization$16.81 billion
P/E Ratio22.72
Dividend Yield1.76%
Beta1.4
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 1.7Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$8.96 per share
Book Value$43.79 per share

Profitability

Net Income$858 million

Miscellaneous

Employees47,000
Market Cap$16.81 billion
Next Earnings Date10/27/2020 (Estimated)
OptionableOptionable
$125.16
+0.65 (+0.52 %)
(As of 08/7/2020 11:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DGX shares have increased by 25.6% and is now trading at $125.23.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quest Diagnostics
.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Quest Diagnostics
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) issued its quarterly earnings data on Thursday, July, 23rd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.41 by $0.01. The medical research company earned $1.83 billion during the quarter, compared to the consensus estimate of $1.81 billion. Quest Diagnostics had a return on equity of 13.78% and a net margin of 9.99%. The firm's revenue was down 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.73 EPS.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Monday, May 18th. Stockholders of record on Wednesday, July 8th will be given a dividend of $0.56 per share on Wednesday, July 22nd. This represents a $2.24 annualized dividend and a dividend yield of 1.79%. The ex-dividend date is Tuesday, July 7th.
View Quest Diagnostics' dividend history
.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Thursday, July, 23rd. The company provided earnings per share guidance of $6.60-$8.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.22. The company issued revenue guidance of $8.0-$8.6 billion, compared to the consensus revenue estimate of $8.52 billion.

What price target have analysts set for DGX?

18 analysts have issued 12 month target prices for Quest Diagnostics' shares. Their forecasts range from $99.00 to $151.00. On average, they expect Quest Diagnostics' stock price to reach $124.56 in the next twelve months. This suggests that the stock has a possible downside of 0.5%.
View analysts' price targets for Quest Diagnostics
.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "Quest Diagnostics reported better-than-expected second-quarter. However the year-over-year decline in adjusted earnings and revenues was concerning. Management noted that base testing volume declined because of the pandemic and was partially offset by increased COVID-19 testing. On a positive note, the company is strongly expanding its COVID-19 testing capacity. Cumulatively, Quest Diagnostics has delivered nearly 20% of all the testing included in this country. Meanwhile, revenue per requisition improved 15.2% primarily driven by reimbursement for COVID-19 molecular testing. A positive demography and strong balance sheet are added benefits. It has also re-established a sturdy 2020 outlook taking into account the uncertainty caused by the pandemic. Quest Diagnostics has outperformed its industry over the past six months." (7/28/2020)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media coverage about DGX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Quest Diagnostics earned a news impact score of 2.1 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Quest Diagnostics
.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 3,190,000 shares, a decline of 6.2% from the July 15th total of 3,400,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the short-interest ratio is presently 1.9 days. Currently, 2.4% of the company's stock are sold short.
View Quest Diagnostics' Current Options Chain
.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Endologix (ELGX), Micron Technology (MU), Gilead Sciences (GILD), Chipotle Mexican Grill (CMG), Procter & Gamble (PG), Cisco Systems (CSCO) and QUALCOMM (QCOM).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Bessemer Group Inc. (0.73%), Sumitomo Mitsui Trust Holdings Inc. (0.72%), LSV Asset Management (0.64%), Scharf Investments LLC (0.52%), First Trust Advisors LP (0.47%) and Swiss National Bank (0.45%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., State of Michigan Retirement System, Russell Investments Group Ltd., Envestnet Asset Management Inc., CWM LLC, Seizert Capital Partners LLC, First Trust Advisors LP, and DNB Asset Management AS. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Robeco Institutional Asset Management B.V., Gradient Investments LLC, LSV Asset Management, SG Americas Securities LLC, UBS Group AG, CHURCHILL MANAGEMENT Corp, and Railway Pension Investments Ltd.
View insider buying and selling activity for Quest Diagnostics
.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $125.23.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $16.82 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.